Key Speakers and Presentations Released for the 13th Annual RNA Therapeutics Conference
SMi Group reports: Ahead of the conference in February 2022, a snapshot or key speakers and presentations are released.
London, United Kingdom, November 19, 2021 --(PR.com)-- SMi Group are delighted to announce the 13th Annual Conference RNA Therapeutics, taking place on the 9th and 10th February 2022 in London, UK. The 2022 Conference is on bolstering the latest advances and opportunities in RNA-based medicine.
Interested parties can register at: http://www.therapeutics-rna.com/PR2PRCOM - take advantage of the early bird offer and register by 30th November and save £200.
Building on the success of previous years, the RNA Therapeutics Conference will bring together industry experts from leading RNA therapeutics companies to gain an expert and holistic view on the latest developments of the industry.
With this in mind, SMi Group have released a snapshot of the speakers and sessions that will be featured during the two day conference, please see below:
Featured Key Conference Speakers:
· Jimmy Weterings, Principal Scientist Oligonucleotide Chemistry, AstraZeneca
· Thomas Thum, Founder and Chief Scientific Officer, Cardior Pharmaceuticals
· Samir Ounzain, CEO, Haya Therapeutics
· David Lowe, Vice President, Research, Evox Therapeutics
· Alfica Sehgal, Vice President, Head of Discovery, CAMP4 Therapeutics
· Punit Seth, Vice President, Medicinal Chemistry, Ionis Pharmaceuticals
· Nagy Habib, Head of HBP Surgery, Co-Founder, Imperial College London and MiNA Therapeutics
· Dong Ki Lee, CEO, OliX Therapeutics
· Martin Akerman, Chief Technology Officer & Co-Founder, Envisagenics
Key Sessions include
Reviewing the Current Environment of R&D and New Technologies
· How have we seen the industry evolve over the past year?
· Significant developments in RNA technologies
· How can the recent acceptance of mRNA vaccines aid further advances in the industry?
· What are the major hurdles facing the industry and a look to new opportunities in the near future
Heinrich Haas, VP RNA Formulation and Drug Delivery, BioNTech
Traversing Protected Tissue Barriers for Oligonucleotide Delivery
· Current challenges in delivery of oligonucleotide therapeutics
· Insights into the use of Transferring receptor ligands and other approaches to optimise delivery
· Case Study: Enhancing potency of oligonucleotide therapeutics in muscle tissues
· A future outlook for enhancing oligonucleotide delivery systems
Punit Seth, Vice President, Medicinal Chemistry, Ionis Pharmaceutical
A Novel microRNA Target Modulates Voltage-Gated Sodium Channels and May be a New Therapeutic Approach in Genetic Epilepsies
· We have identified a novel microRNA dysregulation in drug-resistant epilepsies
· This microRNA represses multiple voltage-gated sodium channels in the brain
· Manipulation of this microRNA can alter brain excitability and may be beneficial in genetic epilepsies
Gareth Morris, ERUK Emerging Leader Research Fellow, University College London
Targeting the Noncoding Genome for the Development of RNA Therapies
· New concepts for the identification of tissue, cell-type, and disease specific regulatory ncRNA targets
· RNA-targeting modalities and approaches to tame the genome’s dark side
· Translational potential of next-generation lncRNA targets
Samir Ounzain, CEO, HAYA Therapeutics
View the agenda and speaker line – up at http://www.therapeutics-rna.com/PR2PRCOM
Sponsors: BIA Separations & eTheRNA Immunotherapies
For sponsorship enquiries contact Alia Malick, Director on +44 (0)20 7827 6164 or e-mail amalick@smi-online.co.uk
For media enquiries or a press pass contact Marketing, Nikisha Galoria on +44 (0) 20 7827 6154 or email ngaloria@smi-online.co.uk
RNA Therapeutics 2022
9 – 10 February 2022
London, UK
#SMiRNA
http://www.therapeutics-rna.com/PR2PRCOM
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Interested parties can register at: http://www.therapeutics-rna.com/PR2PRCOM - take advantage of the early bird offer and register by 30th November and save £200.
Building on the success of previous years, the RNA Therapeutics Conference will bring together industry experts from leading RNA therapeutics companies to gain an expert and holistic view on the latest developments of the industry.
With this in mind, SMi Group have released a snapshot of the speakers and sessions that will be featured during the two day conference, please see below:
Featured Key Conference Speakers:
· Jimmy Weterings, Principal Scientist Oligonucleotide Chemistry, AstraZeneca
· Thomas Thum, Founder and Chief Scientific Officer, Cardior Pharmaceuticals
· Samir Ounzain, CEO, Haya Therapeutics
· David Lowe, Vice President, Research, Evox Therapeutics
· Alfica Sehgal, Vice President, Head of Discovery, CAMP4 Therapeutics
· Punit Seth, Vice President, Medicinal Chemistry, Ionis Pharmaceuticals
· Nagy Habib, Head of HBP Surgery, Co-Founder, Imperial College London and MiNA Therapeutics
· Dong Ki Lee, CEO, OliX Therapeutics
· Martin Akerman, Chief Technology Officer & Co-Founder, Envisagenics
Key Sessions include
Reviewing the Current Environment of R&D and New Technologies
· How have we seen the industry evolve over the past year?
· Significant developments in RNA technologies
· How can the recent acceptance of mRNA vaccines aid further advances in the industry?
· What are the major hurdles facing the industry and a look to new opportunities in the near future
Heinrich Haas, VP RNA Formulation and Drug Delivery, BioNTech
Traversing Protected Tissue Barriers for Oligonucleotide Delivery
· Current challenges in delivery of oligonucleotide therapeutics
· Insights into the use of Transferring receptor ligands and other approaches to optimise delivery
· Case Study: Enhancing potency of oligonucleotide therapeutics in muscle tissues
· A future outlook for enhancing oligonucleotide delivery systems
Punit Seth, Vice President, Medicinal Chemistry, Ionis Pharmaceutical
A Novel microRNA Target Modulates Voltage-Gated Sodium Channels and May be a New Therapeutic Approach in Genetic Epilepsies
· We have identified a novel microRNA dysregulation in drug-resistant epilepsies
· This microRNA represses multiple voltage-gated sodium channels in the brain
· Manipulation of this microRNA can alter brain excitability and may be beneficial in genetic epilepsies
Gareth Morris, ERUK Emerging Leader Research Fellow, University College London
Targeting the Noncoding Genome for the Development of RNA Therapies
· New concepts for the identification of tissue, cell-type, and disease specific regulatory ncRNA targets
· RNA-targeting modalities and approaches to tame the genome’s dark side
· Translational potential of next-generation lncRNA targets
Samir Ounzain, CEO, HAYA Therapeutics
View the agenda and speaker line – up at http://www.therapeutics-rna.com/PR2PRCOM
Sponsors: BIA Separations & eTheRNA Immunotherapies
For sponsorship enquiries contact Alia Malick, Director on +44 (0)20 7827 6164 or e-mail amalick@smi-online.co.uk
For media enquiries or a press pass contact Marketing, Nikisha Galoria on +44 (0) 20 7827 6154 or email ngaloria@smi-online.co.uk
RNA Therapeutics 2022
9 – 10 February 2022
London, UK
#SMiRNA
http://www.therapeutics-rna.com/PR2PRCOM
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Contact
SMi Group
Nikisha Galoria
(0) 20 7827 6154
http://www.therapeutics-rna.com/PR2PRCOM
Nikisha Galoria
(0) 20 7827 6154
http://www.therapeutics-rna.com/PR2PRCOM
Contact
Categories